Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Lee, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y

Pasquinelli, 2000, Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA, Nature, 408, 86, 10.1038/35040556

Reinhart, 2000, The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans, Nature, 403, 901, 10.1038/35002607

Calin, 2002, Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 99, 15524, 10.1073/pnas.242606799

Kozomara, 2011, miRBase: integrating microRNA annotation and deep-sequencing data, Nucleic Acids Res., 39, D152, 10.1093/nar/gkq1027

Lindow, 2012, Discovering the first microRNA-targeted drug, J. Cell Biol., 199, 407, 10.1083/jcb.201208082

Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888

Montgomery, 2006, RNA interference: unraveling a mystery, Nat. Struct. Mol. Biol., 13, 1039, 10.1038/nsmb1206-1039

Lares, 2010, RNAi and small interfering RNAs in human disease therapeutic applications, Trends Biotechnol., 28, 570, 10.1016/j.tibtech.2010.07.009

Hydbring, 2013, Clinical applications of microRNAs, F1000Res., 2, 136, 10.12688/f1000research.2-136.v1

Kim, 2009, Biogenesis of small RNAs in animals, Nat. Rev. Mol. Cell Biol., 10, 126, 10.1038/nrm2632

Axtell, 2011, Vive la différence: biogenesis and evolution of microRNAs in plants and animals, Genome Biol., 12, 221, 10.1186/gb-2011-12-4-221

Ambros, 2004, The functions of animal microRNAs, Nature, 431, 350, 10.1038/nature02871

Meister, 2004, Mechanisms of gene silencing by double-stranded RNA, Nature, 431, 343, 10.1038/nature02873

Hammond, 2000, An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells, Nature, 404, 293, 10.1038/35005107

Wang, 2010, Delivery of siRNA therapeutics: barriers and carriers, AAPS J., 12, 492, 10.1208/s12248-010-9210-4

Stevens, 2011, The role of public-sector research in the discovery of drugs and vaccines, N. Engl. J. Med., 364, 535, 10.1056/NEJMsa1008268

McMillan, 2000, An analysis of the critical role of public science in innovation: the case of biotechnology, Res. Policy, 29, 1, 10.1016/S0048-7333(99)00030-X

Laitala-Leinonen, 2010, Update on the development of microRNA and siRNA molecules as regulators of cell physiology, Recent Pat. DNA Gene Seq., 4, 113, 10.2174/187221510793205755

van Rooij, 2012, Developing microRNA therapeutics, Circ. Res., 110, 496, 10.1161/CIRCRESAHA.111.247916

McLeod, 2011, The ‘real world’ utility of miRNA patents: lessons learned from expressed sequence tags, Nat. Biotechnol., 29, 129, 10.1038/nbt.1765

Davis, 2001, Overview of comments in “Utility Examination Guidelines”, Fed. Regist., 1092

Reynolds, 2000, Pricing human genes: the patent rush pushes on, J. Natl. Cancer Inst., 92, 96, 10.1093/jnci/92.2.96

Lazonick, 2011, US biopharmaceutical finance and the sustainability of the biotech business model, Res. Policy, 40, 1170, 10.1016/j.respol.2011.05.021

Haussecker, 2008, The business of RNAi therapeutics, Hum. Gene Ther., 19, 451, 10.1089/hum.2008.007

Haussecker, 2012, The business of RNAi therapeutics in 2012, Mol. Ther. Nucleic Acids, 1, e8, 10.1038/mtna.2011.9

Jana, 2004, RNA interference: potential therapeutic targets, Appl. Microbiol. Biotechnol., 65, 649, 10.1007/s00253-004-1732-1

Vaishnaw, 2010, A status report on RNAi therapeutics, Silence, 1, 14, 10.1186/1758-907X-1-14

DeVincenzo, 2008, Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV), Antiviral Res., 77, 225, 10.1016/j.antiviral.2007.11.009

Tapper, 2015, Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency, Dig. Dis. Sci., 60, 1589, 10.1007/s10620-014-3490-y

Cartwright, 2012, Alnylam partners with Sanofi’s Genzyme to advance its ALN-TTR programme in Asia-Pacific, PharmaDeals Review 2012

Hanout, 2013, Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development, BioMed Res. Int., 2013, 830837, 10.1155/2013/830837

Nguyen, 2012, Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study), Invest. Ophthalmol. Vis. Sci., 53, 7666, 10.1167/iovs.12-9961

Burnett, 2012, RNA-based therapeutics: current progress and future prospects, Chem. Biol., 19, 60, 10.1016/j.chembiol.2011.12.008

Chertow, 2005, Acute kidney injury, mortality, length of stay, and costs in hospitalized patients, J. Am. Soc. Nephrol., 16, 3365, 10.1681/ASN.2004090740

Troppmann, 1995, Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis, Transplantation, 59, 962, 10.1097/00007890-199504150-00007

Watts, 2010, Clinical status of duplex RNA, Bioorg. Med. Chem. Lett., 20, 3203, 10.1016/j.bmcl.2010.03.109

Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429

Rahman, 2013, RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy, Clin. Cancer Res., 19, 3416, 10.1158/1078-0432.CCR-13-0073

Heidel, 2007, Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo, Clin. Cancer Res., 13, 2207, 10.1158/1078-0432.CCR-06-2218

Heidel, 2007, Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA, Proc. Natl. Acad. Sci. USA, 104, 5715, 10.1073/pnas.0701458104

Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956

Ribas, 2010, Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: results from a first-in-class phase I clinical trial, J. Clin. Oncol., 28, 3022, 10.1200/jco.2010.28.15_suppl.3022

Schultheis, 2014, First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors, J. Clin. Oncol., 32, 4141, 10.1200/JCO.2013.55.0376

Santel, 2010, Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models, Clin. Cancer Res., 16, 5469, 10.1158/1078-0432.CCR-10-1994

Zimmermann, 2006, RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 10.1038/nature04688

Cartwright, 2011, RXi pharmaceuticals looks beyond RNAi therapeutics with Apthera acquisition, PharmaDeals Review, 2011

Libertine, 2014, RXI-109 treatment for proliferative vitreoretinopathy (PVR) and other ocular disorders, Invest. Ophthalmol. Vis. Sci., 55, 1120

Garba, 2010, Bevasiranib for the treatment of wet, age-related macular degeneration, Ophthalmol. Eye Dis., 2, 75, 10.4137/OED.S4878

Singerman, 2009, Combination therapy using the small interfering RNA bevasiranib, Retina, 29, S49, 10.1097/IAE.0b013e3181ad2341

Zhang, 2012, Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma, Nat. Rev. Drug Discov., 11, 541, 10.1038/nrd3745

Gebert, 2014, Miravirsen (SPC3649) can inhibit the biogenesis of miR-122, Nucleic Acids Res., 42, 609, 10.1093/nar/gkt852

Janssen, 2013, Treatment of HCV infection by targeting microRNA, N. Engl. J. Med., 368, 1685, 10.1056/NEJMoa1209026

Okada, 2014, A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression, Genes Dev., 28, 438, 10.1101/gad.233585.113

Xie, 2014, Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer, Gene, 543, 101, 10.1016/j.gene.2014.03.059

Bouchie, 2013, First microRNA mimic enters clinic, Nat. Biotechnol., 31, 577, 10.1038/nbt0713-577

Dubin, 2014, Micro-RNA-122 levels in acute liver failure and chronic hepatitis C, J. Med. Virol., 86, 1507, 10.1002/jmv.23987

Motavaf, 2014, Targeting microRNA-122: walking on cutting edge of hepatitis C virus infection therapy, Acta Virol., 58, 301, 10.4149/av_2014_04_301

Gomez, 2015, Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways, J. Clin. Invest., 125, 141, 10.1172/JCI75852

Chau, 2012, MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways, Sci. Transl. Med., 4, 121ra118, 10.1126/scitranslmed.3003205

Grueter, 2012, A cardiac microRNA governs systemic energy homeostasis by regulation of MED13, Cell, 149, 671, 10.1016/j.cell.2012.03.029

Hennessy, 2013, Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline, J. Cardiovasc. Pharmacol., 62, 247, 10.1097/FJC.0b013e31829d48bf

Montgomery, 2011, Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure, Circulation, 124, 1537, 10.1161/CIRCULATIONAHA.111.030932

Aartsma-Rus, 2009, Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms, Mol. Ther., 17, 548, 10.1038/mt.2008.205

van Rooij, 2007, Control of stress-dependent cardiac growth and gene expression by a microRNA, Science, 316, 575, 10.1126/science.1139089

Rasmussen, 2011, The miR-144/451eGFP allele, a novel tool for resolving the erythroid potential of hematopoietic precursors, Blood, 118, 2988, 10.1182/blood-2011-04-350728

Rasmussen, 2010, The miR-144/451 locus is required for erythroid homeostasis, J. Exp. Med., 207, 1351, 10.1084/jem.20100458

Patrick, 2010, Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3ζ, Genes Dev., 24, 1614, 10.1101/gad.1942810

Caldwell, 2000, Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens, Curr. Opin. Drug Discov. Devel., 3, 30

Ruiz-Garcia, 2008, Pharmacokinetics in drug discovery, J. Pharm. Sci., 97, 654, 10.1002/jps.21009

Guengerich, 2006, Cytochrome P450s and other enzymes in drug metabolism and toxicity, AAPS J., 8, E101, 10.1208/aapsj080112

Giacomini, 2010, Membrane transporters in drug development, Nat. Rev. Drug Discov., 9, 215, 10.1038/nrd3028

Khatsenko, 2000, Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length, Antisense Nucleic Acid Drug Dev., 10, 35, 10.1089/oli.1.2000.10.35

Stenvang, 2012, Inhibition of microRNA function by antimiR oligonucleotides, Silence, 3, 1, 10.1186/1758-907X-3-1

Levin, 1999, A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides, Biochim. et Biophys. Acta, 1489, 69, 10.1016/S0167-4781(99)00140-2

Elmén, 2008, LNA-mediated microRNA silencing in non-human primates, Nature, 452, 896, 10.1038/nature06783

Elmén, 2008, Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver, Nucleic Acids Res., 36, 1153, 10.1093/nar/gkm1113

Krützfeldt, 2007, Specificity, duplex degradation and subcellular localization of antagomirs, Nucleic Acids Res., 35, 2885, 10.1093/nar/gkm024

Krützfeldt, 2005, Silencing of microRNAs in vivo with ‘antagomirs’, Nature, 438, 685, 10.1038/nature04303

Lindholm, 2012, PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates, Mol. Ther., 20, 376, 10.1038/mt.2011.260

Broderick, 2011, MicroRNA therapeutics, Gene Ther., 18, 1104, 10.1038/gt.2011.50

Hong, 2014, Functional nanostructures for effective delivery of small interfering RNA therapeutics, Theranostics, 4, 1211, 10.7150/thno.8491

Miller, 2013, Delivery of RNAi therapeutics: work in progress, Expert Rev. Med. Devices, 10, 781, 10.1586/17434440.2013.855471

Love, 2010, Lipid-like materials for low-dose, in vivo gene silencing, Proc. Natl. Acad. Sci. USA, 107, 1864, 10.1073/pnas.0910603106

Sioud, 2015

Wang, 2010, siRNAs as potential drugs, Drug Discov. Today. Technol., 7, e95, 10.1016/j.ddtec.2010.11.011